Regeneron (NASDAQ: REGN) is a biotech company with over 35 years of experience, generating billions in revenue. Known for Dupixent, a blockbuster drug for inflammation, and Eylea for eye diseases, Regeneron has a strong pipeline with over a dozen candidates in phase 3 trials. Trading at 17x forward earnings, it’s a no-brainer buy for long-term growth.

Read more at Yahoo Finance: 1 No-Brainer Biotech Stock To Buy Today and Never Sell